Price T Rowe Associates Inc Ocugen, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Ocugen, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 123,718 shares of OCGN stock, worth $115,057. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123,718
Previous 113,072
9.42%
Holding current value
$115,057
Previous $91,000
3.3%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding OCGN
# of Institutions
118Shares Held
75.1MCall Options Held
200KPut Options Held
151K-
Black Rock Inc. New York, NY17.9MShares$16.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.7MShares$15.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$6.41 Million0.0% of portfolio
-
State Street Corp Boston, MA5.93MShares$5.52 Million0.0% of portfolio
-
Ubs Group Ag4.37MShares$4.06 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $201M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...